MedTrace Logo

STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial

NCT01702636 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-02-26

No results posted yet for this study

Summary

The aim of the study is to test if intracerebral haemorrhage (ICH) patients who have contrast extravasation on computed tomography angiography, the "spot sign", have lower rates of haematoma growth when treated with tranexamic acid within 4.5 hours of stroke onset, compared to placebo.

Conditions

  • Intracerebral Haemorrhage
  • Stroke

Interventions

DRUG

Tranexamic Acid

DRUG

Placebo

Sponsors & Collaborators

  • Neuroscience Trials Australia

    lead OTHER

Principal Investigators

  • Atte Meretoja, MD · The Florey Institute of Neuroscience and Mental Health

  • Geoffrey A Donnan, MD · The Florey Institute of Neuroscience and Mental Health

  • Stephen M Davis, MD · Melbourne Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2019-08-14
Completion
2019-12-31

Countries

  • Australia
  • Finland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01702636 on ClinicalTrials.gov